Delcath Systems, Inc. (DCTH)
NASDAQ: DCTH · Real-Time Price · USD
9.70
+0.06 (0.62%)
Nov 28, 2025, 4:00 PM EST - Market closed
Delcath Systems Revenue
Delcath Systems had revenue of $20.56M in the quarter ending September 30, 2025, with 83.60% growth. This brings the company's revenue in the last twelve months to $79.60M, up 251.54% year-over-year. In the year 2024, Delcath Systems had annual revenue of $37.21M with 1,701.69% growth.
Revenue (ttm)
$79.60M
Revenue Growth
+251.54%
P/S Ratio
4.23
Revenue / Employee
$829,198
Employees
96
Market Cap
342.54M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 37.21M | 35.14M | 1,701.69% |
| Dec 31, 2023 | 2.07M | -654.00K | -24.05% |
| Dec 31, 2022 | 2.72M | -836.00K | -23.52% |
| Dec 31, 2021 | 3.56M | 1.91M | 115.98% |
| Dec 31, 2020 | 1.65M | 66.00K | 4.18% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
DCTH News
- 10 days ago - Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program - Business Wire
- 12 days ago - Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma - Business Wire
- 16 days ago - Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 17 days ago - Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients - Business Wire
- 24 days ago - Delcath Systems to Participate in Upcoming Investor Conferences - Business Wire
- 24 days ago - Delcath: Temporary Headwinds Are No Cause For Concern - Seeking Alpha
- 26 days ago - Delcath Systems, Inc. (DCTH) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 26 days ago - Delcath Systems Reports Third Quarter 2025 Results and Business Highlights - Business Wire